Angiogenesis and the tumor microenvironment: Vascular endothelial growth factor and beyond

Seminars in Oncology

Volumn 41, Issue 2, 2014, Pages 235-251

  Mittal, Kriti ^a   Ebos, John ^b   Rini, Brian ^a  

^a TAUSSIG CANCER INSTITUTE   (United States)

^b ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ANGIOPOIETIN; ANGIOPOIETIN 1; ANGIOPOIETIN 2; AXITINIB; BEVACIZUMAB; CABOZANTINIB; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ENDOCRINE GLAND DERIVED VASCULAR ENDOTHELIAL GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 2; GELATINASE B; HYPOXIA INDUCIBLE FACTOR 1; INTERLEUKIN 10; INTERLEUKIN 17; INTERLEUKIN 8; NEUTROPHIL COLLAGENASE; PAZOPANIB; PLATELET DERIVED GROWTH FACTOR; PLATELET DERIVED GROWTH FACTOR B; PLATELET DERIVED GROWTH FACTOR BB; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; REACTIVE OXYGEN METABOLITE; SCATTER FACTOR; SORAFENIB; SUNITINIB; UVOMORULIN; VANDETANIB; VASCULOTROPIN; VASCULOTROPIN RECEPTOR;

ADAPTIVE IMMUNITY; ANGIOGENESIS; ANTIANGIOGENIC THERAPY; ANTIGEN RECOGNITION; ARTERY MUSCLE; ARTICLE; B LYMPHOCYTE; BASEMENT MEMBRANE; BINDING SITE; BREAST CANCER; CAPILLARY ENDOTHELIUM; CELL MIGRATION; CHRONIC MYELOMONOCYTIC LEUKEMIA; COLORECTAL CANCER; DENDRITIC CELL; DERMATOFIBROSARCOMA PROTUBERANS; ENDOTHELIUM CELL; EOSINOPHIL; EPITHELIAL MESENCHYMAL TRANSITION; ESOPHAGEAL SQUAMOUS CELL CARCINOMA; EXTRACELLULAR MATRIX; GASTROINTESTINAL STROMAL TUMOR; GENE EXPRESSION; GENE LOCUS; GRANULOCYTE; GROWTH STIMULATION; HEMATOPOIETIC STEM CELL; HUMAN; IMMUNE EVASION; IMMUNE RESPONSE; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; INNATE IMMUNITY; KIDNEY CARCINOMA; KIDNEY METASTASIS; LUNG SMALL CELL CANCER; LYMPHOCYTE; MACROPHAGE; MAST CELL; MESENCHYMAL STEM CELL; MOLECULAR INTERACTION; MONOCYTE; MYELOID PROGENITOR CELL; MYOFIBROBLAST; NATURAL KILLER CELL; NEUTROPHIL; NONHUMAN; NUCLEIC ACID HYBRIDIZATION; OLIGODENDROGLIOMA; OXIDATIVE STRESS; PANCREATIC NEUROENDOCRINE TUMOR; PARACRINE SIGNALING; PERICYTE; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PHENOTYPE; PHENOTYPIC VARIATION; POINT MUTATION; PRIORITY JOURNAL; PROMOTER REGION; SMOOTH MUSCLE FIBER; STROMA; SUPPRESSOR CELL; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; THROMBOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; TUMOR VASCULARIZATION; UPREGULATION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

ANGIOGENESIS INHIBITORS; ANIMALS; ANTINEOPLASTIC AGENTS; BIOLOGICAL MARKERS; CELL TRANSFORMATION, NEOPLASTIC; CYTOKINES; ENDOTHELIAL CELLS; HUMANS; IMMUNE SYSTEM; MICE; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC; PLATELET-DERIVED GROWTH FACTOR; STROMAL CELLS; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84899732336     PISSN: 00937754     EISSN: 15328708     Source Type: Journal    
DOI: 10.1053/j.seminoncol.2014.02.007     Document Type: Article

References (196)

1. J.W. Rak St, B.D. Croix, and R.S. Kerbel Consequences of angiogenesis for tumor progression, metastasis and cancer therapy Anticancer Drugs 6 1995 3 18
2. F. Shojaei, and N. Ferrara Role of the microenvironment in tumor growth and in refractoriness/resistance to anti-angiogenic therapies Drug Resistance Updates 11 2008 219 230
3. L.A. Liotta, and E.C. Kohn The microenvironment of the tumour-host interface Nature 411 2001 375 379
4. Y. Yang, M. Sun, L. Wang, and B. Jiao HIFs, angiogenesis, and cancer J Cell Biochem 114 2013 967 974
5. J. Folkman Tumor angiogenesis: therapeutic implications N Engl J Med 285 1971 1182 1186
6. J.C. Yang, L. Haworth, and R.M. Sherry et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer N Engl J Med 349 2003 427 434
7. M.R. Junttila, and F.J. de Sauvage Influence of tumour micro-environment heterogeneity on therapeutic response Nature 501 2013 346 354
8. D.F. Quail, and J.A. Joyce Microenvironmental regulation of tumor progression and metastasis Nat Med 19 2013 1423 1437
9. P. Friedl, and S. Alexander Cancer invasion and the microenvironment: plasticity and reciprocity Cell 147 2011 992 1009
10. J.P. Thiery, H. Acloque, R.Y. Huang, and M.A. Nieto Epithelial- mesenchymal transitions in development and disease Cell 139 2009 871 890
11. Q. Wu, X. Hou, and J. Xia et al. Emerging roles of PDGF-D in EMT progression during tumorigenesis Cancer Treat Rev 39 2013 640 646
12. P. Carmeliet Mechanisms of angiogenesis and arteriogenesis Nat Med 6 2000 389 395
13. H. Gerhardt, M. Golding, and M. Fruttiger et al. VEGF guides angiogenic sprouting utilizing endothelial tip cell filopodia J Cell Biol 161 2003 1163 1177
14. M. Franco, P. Roswall, E. Cortez, D. Hanahan, and K. Pietras Pericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expression Blood 118 2011 2906 2917
15. J. Welti, S. Loges, S. Dimmeler, and P. Carmeliet Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer J Clin Invest 123 2013 3190 3200
16. N.R. Smith, D. Baker, and M. Farren et al. Tumor stromal architecture can define the intrinsic tumor response to VEGF-targeted therapy Clin Cancer Res 19 2013 6943 6956
17. P.P. Provenzano, K.W. Eliceiri, J.M. Campbell, D.R. Inman, J.G. White, and P.J. Keely Collagen reorganization at the tumor-stromal interface facilitates local invasion BMC Med 4 2006 38
18. P. Saharinen, and K. Alitalo The yin, the yang, and the angiopoietin-1 J Clin Invest 121 2011 2157 2159
19. R.S. Watnick The role of the tumor microenvironment in regulating angiogenesis Cold Spring Harbor Perspect Med 2 2012 a006676
20. M.C. Schmid, and J.A. Varner Myeloid cells in the tumor microenvironment: modulation of tumor angiogenesis and tumor inflammation J Oncol 2010 2010 201026
21. D.I. Gabrilovich, S. Ostrand-Rosenberg, and V. Bronte Coordinated regulation of myeloid cells by tumours Nat Rev Immunol 12 2012 253 268
22. T.F. Gajewski, H. Schreiber, and Y.X. Fu Innate and adaptive immune cells in the tumor microenvironment Nat Immunol 14 2013 1014 1022
23. F. Shojaei, X. Wu, and A.K. Malik et al. Tumor refractoriness to anti-VEGF treatment is mediated by CD11b+Gr1+ myeloid cells Nat Biotechnol 25 2007 911 920
24. J. Finke, J. Ko, B. Rini, P. Rayman, J. Ireland, and P. Cohen MDSC as a mechanism of tumor escape from sunitinib mediated anti-angiogenic therapy Int Immunopharmacol 11 2011 856 861
25. A.S. Chung, X. Wu, and G. Zhuang et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy Nat Med 19 2013 1114 1123
26. C. Sunderkotter, K. Steinbrink, M. Goebeler, R. Bhardwaj, and C. Sorg Macrophages and angiogenesis J Leukoc Biol 55 1994 410 422
27. E. Giraudo, M. Inoue, and D. Hanahan An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis J Clin Invest 114 2004 623 633
28. R. Hildenbrand, I. Dilger, A. Horlin, and H.J. Stutte Urokinase and macrophages in tumour angiogenesis Br J Cancer 72 1995 818 823
29. R.D. Leek, and A.L. Harris Tumor-associated macrophages in breast cancer J Mammary Gland Biol Neoplasia 7 2002 177 189
30. A. Nishie, M. Ono, and T. Shono et al. Macrophage infiltration and heme oxygenase-1 expression correlate with angiogenesis in human gliomas Clin Cancer Res 5 1999 1107 1113
31. D. Gabrilovich Mechanisms and functional significance of tumour-induced dendritic-cell defects Nat Rev Immunol 4 2004 941 952
32. I. Fricke, and D.I. Gabrilovich Dendritic cells and tumor microenvironment: a dangerous liaison Immunol Invest 35 2006 459 483
33. J.R. Conejo-Garcia, F. Benencia, and M.C. Courreges et al. Tumor-infiltrating dendritic cell precursors recruited by a beta-defensin contribute to vasculogenesis under the influence of Vegf-A Nat Med 10 2004 950 958
34. O. Fainaru, N. Almog, and C.W. Yung et al. Tumor growth and angiogenesis are dependent on the presence of immature dendritic cells FASEB J 24 2010 1411 1418
35. C.A. Chambers, M.S. Kuhns, J.G. Egen, and J.P. Allison CTLA-4-mediated inhibition in regulation of T cell responses: mechanisms and manipulation in tumor immunotherapy Ann Rev Immunol 19 2001 565 594
36. T.J. Harris, and C.G. Drake Primer on tumor immunology and cancer immunotherapy J Immunother Cancer 1 2013 12
37. J. Duraiswamy, G. Freeman, and G. Coukos Replenish the source within: rescuing tumor-infiltrating lymphocytes by double checkpoint blockade Oncoimmunology 2 2013 e25912
38. D. Ribatti, G. Ranieri, A. Basile, A. Azzariti, A. Paradiso, and A. Vacca Tumor endothelial markers as a target in cancer Exp Opin Therapeut Targets 16 2012 1215 1225
39. P.L. Triozzi, S. Achberger, W. Aldrich, A.D. Singh, R. Grane, and E.C. Borden The association of blood angioregulatory microRNA levels with circulating endothelial cells and angiogenic proteins in patients receiving dacarbazine and interferon J Translat Med 10 2012 241
40. A.D. Blann, A. Woywodt, and F. Bertolini et al. Circulating endothelial cells. Biomarker of vascular disease Thromb Haemost 93 2005 228 235
41. J. Folkman Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Disc 6 2007 273 286
42. F. Bertolini, P. Mancuso, L. Benayoun, S. Gingis-Velitski, and Y. Shaked Evaluation of circulating endothelial precursor cells in cancer patients Methods Mol Biol 904 2012 165 172
43. E.M. Battinelli, B.A. Markens, and J.E. Italiano Jr Release of angiogenesis regulatory proteins from platelet alpha granules: modulation of physiologic and pathologic angiogenesis Blood 118 2011 1359 1369
44. J.E. Italiano Jr, J.L. Richardson, and S. Patel-Hett et al. Angiogenesis is regulated by a novel mechanism: pro- and antiangiogenic proteins are organized into separate platelet alpha granules and differentially released Blood 111 2008 1227 1233
45. S.G. Ball, C.A. Shuttleworth, and C.M. Kielty Vascular endothelial growth factor can signal through platelet-derived growth factor receptors J Cell Biol 177 2007 489 500
46. J. Folkman, E. Merler, C. Abernathy, and G. Williams Isolation of a tumor factor responsible for angiogenesis J Exp Med 133 1971 275 288
47. D.R. Senger, S.J. Galli, A.M. Dvorak, C.A. Perruzzi, V.S. Harvey, and H.F. Dvorak Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid Science 219 1983 983 985
48. D.W. Leung, G. Cachianes, W.J. Kuang, D.V. Goeddel, and N. Ferrara Vascular endothelial growth factor is a secreted angiogenic mitogen Science 246 1989 1306 1309
49. D.J. Hicklin, and L.M. Ellis Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis J Clin Oncol 23 2005 1011 1027
50. M.J. Wang, P.R. Crisostomo, C. Herring, K.K. Meldrum, and D.R. Meldrum Human progenitor cells from bone marrow or adipose tissue produce VEGF, HGF, and IGF-I in response to TNF by a p38 MAPK-dependent mechanism Am J Physiol Reg I 291 2006 R880 R884
51. F. Mor, F.J. Quintana, and I.R. Cohen Angiogenesis-inflammation cross-talk: vascular endothelial growth factor is secreted by activated T cells and induces Th1 polarization J Immunol 172 2004 4618 4623
52. N.A. Dallas, F. Fan, and M.J. Gray et al. Functional significance of vascular endothelial growth factor receptors on gastrointestinal cancer cells Cancer Metastasis Rev 26 2007 433 441
53. N. Ferrara, and T. DavisSmyth The biology of vascular endothelial growth factor Endocr Rev 18 1997 4 25
54. F. Baffert, T. Le, and B. Sennino et al. Cellular changes in normal blood capillaries undergoing regression after inhibition of VEGF signaling Am J Physiol Heart C 290 2006 H547 H559
55. T. Kamba, B.Y.Y. Tam, and H. Hashizume et al. VEGF-dependent plasticity of fenestrated capillaries in the normal adult microvasculature Am J Physiol Heart C 290 2006 H560 H576
56. S. Lee, T.T. Chen, and C.L. Barber et al. Autocrine VEGF signaling is required for vascular homeostasis Cell 130 2007 691 703
57. D.R. Senger Vascular endothelial growth factor: much more than an angiogenesis factor Mol Biol Cell 21 2010 377 379
58. H.F. Dvorak Vascular permeability factor/vascular endothelial growth factor: a critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy J Clin Oncol 20 2002 4368 4380
59. D.O. Bates, and S.J. Harper Regulation of vascular permeability by vascular endothelial growth factors Vasc Pharmacol 39 2002 225 237
60. I. Zachary Signaling mechanisms mediating vascular protective actions of vascular endothelial growth factor Am J Physiol Cell Ph 280 2001 C1375 C1386
61. A. Hoeben, B. Landuyt, M.S. Highley, H. Wildiers, A.T. Van Oosterom, and E.A. De Bruijn Vascular endothelial growth factor and angiogenesis Pharmacol Rev 56 2004 549 580
62. E. Geretti, and M. Klagsbrun Neuropilins novel targets for anti-angiogenesis therapies Cell Adhes Migr 1 2007
63. M. Fukasawa, A. Matsushita, and M. Korc Neuropilin-1 interacts with integrin beta 1 and modulates pancreatic cancer cell growth, survival and invasion Cancer Biol Ther 6 2007 1173 1180
64. S. Banerjee, K. Sengupta, and K. Dhar et al. Breast cancer cells secreted platelet-derived growth factor-induced motility of vascular smooth muscle cells is mediated through neuropilin-1 Mol Carcinogen 45 2006 871 880
65. A. Fantin, Q. Schwarz, K. Davidson, E.M. Normando, L. Denti, and C. Ruhrberg The cytoplasmic domain of neuropilin 1 is dispensable for angiogenesis, but promotes the spatial separation of retinal arteries and veins Development 138 2011 4185 4191
66. I. Nazarenko, S.M. Hede, and X.B. He et al. PDGF and PDGF receptors in glioma Upsala J Med Sci 117 2012 99 112
67. N. Kohler, and A. Lipton Platelets as a source of fibroblast growth-promoting activity Exp Cell Res 87 1974 297 301
68. R. Ross, J. Glomset, B. Kariya, and L. Harker A platelet-dependent serum factor that stimulates the proliferation of arterial smooth muscle cells in vitro Proc Natl Acad Sci U S A 71 1974 1207 1210
69. B. Westermark, and A. Wasteson A platelet factor stimulating human normal glial cells Exp Cell Res 98 1976 170 174
70. J. Andrae, R. Gallini, and C. Betsholtz Role of platelet-derived growth factors in physiology and medicine Genes Dev 22 2008 1276 1312
71. A. Abramsson, P. Lindblom, and C. Betsholtz Endothelial and nonendothelial sources of PDGF-B regulate pericyte recruitment and influence vascular pattern formation in tumors J Clin Invest 112 2003 1142 1151
72. C.H. Heldin Autocrine PDGF stimulation in malignancies Upsala J Med Sci 117 2012 83 91
73. M. Hermanson, K. Funa, and M. Hartman et al. Platelet-derived growth factor and its receptors in human glioma tissue: expression of messenger RNA and protein suggests the presence of autocrine and paracrine loops Cancer Res 52 1992 3213 3219
74. J. Dong, J. Grunstein, and M. Tejada et al. VEGF-null cells require PDGFR alpha signaling-mediated stromal fibroblast recruitment for tumorigenesis EMBO J 23 2004 2800 2810
75. L. Li, D.K. Blumenthal, C.M. Terry, Y. He, M.L. Carlson, and A.K. Cheung PDGF-induced proliferation in human arterial and venous smooth muscle cells: molecular basis for differential effects of PDGF isoforms J Cell Biochem 112 2011 289 298
76. M.C. Heinrich, C.L. Corless, and A. Duensing et al. PDGFRA activating mutations in gastrointestinal stromal tumors Science 299 2003 708 710
77. M.K. Magnusson, K.E. Meade, R. Nakamura, J. Barrett, and C.E. Dunbar Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene Blood 100 2002 1088 1091
78. T.P. Fleming, A. Saxena, and W.C. Clark et al. Amplification and/or overexpression of platelet-derived growth factor receptors and epidermal growth factor receptor in human glial tumors Cancer Res 52 1992 4550 4553
79. M. Puputti, O. Tynninen, and H. Sihto et al. Amplification of KIT, PDGFRA, VEGFR2, and EGFR in gliomas Mol Cancer Res 4 2006 927 934
80. J.S. Smith, X.Y. Wang, and J. Qian et al. Amplification of the platelet-derived growth factor receptor-A (PDGFRA) gene occurs in oligodendrogliomas with grade IV anaplastic features J Neuropathol Exp Neurol 59 2000 495 503
81. H. Arai, T. Ueno, and A. Tangoku et al. Detection of amplified oncogenes by genome DNA microarrays in human primary esophageal squamous cell carcinoma: comparison with conventional comparative genomic hybridization analysis Cancer Genetics Cytogenet 146 2003 16 21
82. R.K. Jain, and M.F. Booth What brings pericytes to tumor vessels? J Clin Invest 112 2003 1134 1136
83. M. Hellstrom, M. Kalen, P. Lindahl, A. Abramsson, and C. Betsholtz Role of PDGF-B and PDGFR-beta in recruitment of vascular smooth muscle cells and pericytes during embryonic blood vessel formation in the mouse Development 126 1999 3047 3055
84. C. Anderberg, H. Li, and L. Fredriksson et al. Paracrine signaling by platelet-derived growth factor-CC promotes tumor growth by recruitment of cancer-associated fibroblasts Cancer res 69 2009 369 378
85. K. Forsberg, I. Valyi-Nagy, C.H. Heldin, M. Herlyn, and B. Westermark Platelet-derived growth factor (PDGF) in oncogenesis: development of a vascular connective tissue stroma in xenotransplanted human melanoma producing PDGF-BB Proc Natl Acad Sci U S A 90 1993 393 397
86. Y. Saito, J. Haendeler, Y. Hojo, K. Yamamoto, and B.C. Berk Receptor heterodimerization: essential mechanism for platelet-derived growth factor-induced epidermal growth factor receptor transactivation Mol Cellular Biol 21 2001 6387 6394
87. L.J. Nissen, R. Cao, and E.M. Hedlund et al. Angiogenic factors FGF2 and PDGF-BB synergistically promote murine tumor neovascularization and metastasis J Clin Invest 117 2007 2766 2777
88. V.G. Cooke, V.S. LeBleu, and D. Keskin et al. Pericyte depletion results in hypoxia-associated epithelial-to-mesenchymal transition and metastasis mediated by met signaling pathway Cancer Cell 21 2012 66 81
89. D.M. Valenzuela, J.A. Griffiths, and J. Rojas et al. Angiopoietins 3 and 4: diverging gene counterparts in mice and humans Proc Natl Acad Sci U S A 96 1999 1904 1909
90. S. Davis, and G.D. Yancopoulos The angiopoietins: Yin and Yang in angiogenesis Curr Topics Microbiol Immunol 237 1999 173 185
91. W.S. Shim, I.A. Ho, and P.E. Wong Angiopoietin: a TIE(d) balance in tumor angiogenesis Mol Cancer Res 5 2007 655 665
92. S. Davis, T.H. Aldrich, and P.F. Jones et al. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning Cell 87 1996 1161 1169
93. C. Suri, P.F. Jones, and S. Patan et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis Cell 87 1996 1171 1180
94. M. Jeansson, A. Gawlik, and G. Anderson et al. Angiopoietin-1 is essential in mouse vasculature during development and in response to injury J Clin Invest 121 2011 2278 2289
95. T. Hawighorst, M. Skobe, and M. Streit et al. Activation of the tie2 receptor by angiopoietin-1 enhances tumor vessel maturation and impairs squamous cell carcinoma growth Am J Pathol 160 2002 1381 1392
96. J. K.O. Cai, G.M. Smith, P. Hykin, and M. Boulton The angiopoietin/Tie-2 system regulates pericyte survival and recruitment in diabetic retinopathy Invest Ophthalmol Visual Sci 49 2008 2163 2171
97. C. Suri, J. McClain, and G. Thurston et al. Increased vascularization in mice overexpressing angiopoietin-1 Science 282 1998 468 471
98. M. Gardizi, C. Kurschat, and A. Riese et al. A decreased ratio between serum levels of the antagonistic angiopoietins 1 and 2 indicates tumour progression of malignant melanoma Arch Dermatol Res 304 2012 397 400
99. I. Helfrich, L. Edler, and A. Sucker et al. Angiopoietin-2 levels are associated with disease progression in metastatic malignant melanoma Clin Cancer Res 15 2009 1384 1392
100. P. Kumpers, C. Koenecke, and H. Hecker et al. Angiopoietin-2 predicts disease-free survival after allogeneic stem cell transplantation in patients with high-risk myeloid malignancies Blood 112 2008 2139 2148
101. C. Schliemann, R. Bieker, and N. Thoennissen et al. Circulating angiopoietin-2 is a strong prognostic factor in acute myeloid leukemia Leukemia 21 2007 1901 1906
102. T. Cascone, and J.V. Heymach Targeting the angiopoietin/Tie2 pathway: cutting tumor vessels with a double-edged sword? J Clin Oncol 30 2012 441 444
103. T. Nakamura, and S. Mizuno The discovery of hepatocyte growth factor (HGF) and its significance for cell biology, life sciences and clinical medicine Proc Jpn Acad Series B 86 2010 588 610
104. G.V. Scagliotti, S. Novello, and J. von Pawel The emerging role of MET/HGF inhibitors in oncology Cancer Treat Rev 39 2013 793 801
105. C. Birchmeier, W. Birchmeier, E. Gherardi, and Woude GF. Vande Met, metastasis, motility and more Nature Rev Mol Cell Biol 4 2003 915 925
106. J.G. Christensen, J. Burrows, and R. Salgia c-Met as a target for human cancer and characterization of inhibitors for therapeutic intervention Cancer Lett 225 2005 1 26
107. S. Hara, K. Nakashiro, S.K. Klosek, T. Ishikawa, S. Shintani, and H. Hamakawa Hypoxia enhances c-Met/HGF receptor expression and signaling by activating HIF-1alpha in human salivary gland cancer cells Oral Oncol 42 2006 593 598
108. Y. Nakamura, R. Morishita, and J. Higaki et al. Hepatocyte growth factor is a novel member of the endothelium-specific growth factors: additive stimulatory effect of hepatocyte growth factor with basic fibroblast growth factor but not with vascular endothelial growth factor J Hypertens 14 1996 1067 1072
109. F. Bussolino, M.F. Di Renzo, and M. Ziche et al. Hepatocyte growth factor is a potent angiogenic factor which stimulates endothelial cell motility and growth J Cell Biol 119 1992 629 641
110. K. Yamamoto, R. Morishita, and S. Hayashi et al. Contribution of Bcl-2, but not Bcl-xL and Bax, to antiapoptotic actions of hepatocyte growth factor in hypoxia-conditioned human endothelial cells Hypertension 37 2001 1341 1348
111. X. Xin, S. Yang, and G. Ingle et al. Hepatocyte growth factor enhances vascular endothelial growth factor-induced angiogenesis in vitro and in vivo Am J Pathol 158 2001 1111 1120
112. S. Scarpino, A. Di Napoli, G. Taraboletti, A. Cancrini, and L.P. Ruco Hepatocyte growth factor (HGF) downregulates thrombospondin 1 (TSP-1) expression in thyroid papillary carcinoma cells J Pathol 205 2005 50 56
113. K.V. Lu, J.P. Chang, and C.A. Parachoniak et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex Cancer Cell 22 2012 21 35
114. B. Sennino, T. Ishiguro-Oonuma, B.J. Schriver, J.G. Christensen, and D.M. McDonald Inhibition of c-Met reduces lymphatic metastasis in RIP-Tag2 transgenic mice Cancer Res 73 2013 3692 3703
115. F.M. Yakes, J. Chen, and J. Tan et al. Cabozantinib (XL184), a novel MET and VEGFR2 inhibitor, simultaneously suppresses metastasis, angiogenesis, and tumor growth Mol Cancer Ther 10 2011 2298 2308
116. B. Sennino, T. Ishiguro-Oonuma, and Y. Wei et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors Cancer Disc 2 2012 270 287
117. E. Gherardi, W. Birchmeier, C. Birchmeier, and G. Vande Woude Targeting MET in cancer: rationale and progress Nat Rev Cancer 12 2012 89 103
118. C.M. Bullock, J.D. Li, and Q.Y. Zhou Structural determinants required for the bioactivities of prokineticins and identification of prokineticin receptor antagonists Mol Pharmacol 65 2004 582 588
119. S. Negrier, and E. Raymond Antiangiogenic treatments and mechanisms of action in renal cell carcinoma Invest New Drugs 30 2012 1791 1801
120. J. LeCouter, R. Lin, and M. Tejada et al. The endocrine-gland-derived VEGF homologue Bv8 promotes angiogenesis in the testis: Localization of Bv8 receptors to endothelial cells Proc Natl Acad Sci U S A 100 2003 2685 2690
121. E.S. Ngan, and P.K. Tam Prokineticin-signaling pathway Int J Biochem Cell Biol 40 2008 1679 1684
122. C. Martucci, S. Franchi, and E. Giannini et al. Bv8, the amphibian homologue of the mammalian prokineticins, induces a proinflammatory phenotype of mouse macrophages Br J Pharmacol 147 2006 225 234
123. F. Shojaei, X. Wu, and X. Qu et al. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models Proc Natl Acad Sci U S A 106 2009 6742 6747
124. F. Shojaei, X. Wu, and C. Zhong et al. Bv8 regulates myeloid-cell- dependent tumour angiogenesis Nature 450 2007 825 831
125. H. Xin, R. Lu, and H. Lee et al. G-protein-coupled receptor agonist BV8/prokineticin-2 and STAT3 protein form a feed-forward loop in both normal and malignant myeloid cells J Biol Chem 288 2013 13842 13849
126. Y. Mao, E.T. Keller, D.H. Garfield, K. Shen, and J. Wang Stromal cells in tumor microenvironment and breast cancer Cancer Metastasis Rev 32 2013 303 315
127. R.N. Gacche, and R.J. Meshram Targeting tumor micro-environment for design and development of novel anti-angiogenic agents arresting tumor growth Prog Biophys Mol Biol 113 2013 333 354
128. J.M. Ebos, and R.S. Kerbel Antiangiogenic therapy: impact on invasion, disease progression, and metastasis Nat Rev Clin Oncol 8 2011 210 221
129. C. Devaud, L.B. John, J.A. Westwood, P.K. Darcy, and M.H. Kershaw Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy Oncoimmunology 2 2013 e25961
130. M. Santoni, F. Massari, and C. Amantini et al. Emerging role of tumor-associated macrophages as therapeutic targets in patients with metastatic renal cell carcinoma Cancer Immunol Immunother 62 2013 1757 1768
131. H. Hurwitz, L. Fehrenbacher, and W. Novotny et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer N Engl J Med 350 2004 2335 2342
132. H.S. Friedman, M.D. Prados, and P.Y. Wen et al. Bevacizumab alone and in combination with irinotecan in recurrent glioblastoma J Clin Oncol 27 2009 4733 4740
133. A. Sandler, J. Yi, and S. Dahlberg et al. Treatment outcomes by tumor histology in Eastern Cooperative Group Study E4599 of bevacizumab with paclitaxel/carboplatin for advanced non-small cell lung cancer J Thorac Oncol 5 2010 1416 1423
134. B. Escudier, T. Eisen, and W.M. Stadler et al. Sorafenib in advanced clear-cell renal-cell carcinoma N Engl J Med 356 2007 125 134
135. J.M. Llovet, S. Ricci, and V. Mazzaferro et al. Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 2008 378 390
136. C.N. Sternberg, I.D. Davis, and J. Mardiak et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
137. R.J. Motzer, B. Escudier, and P. Tomczak et al. Axitinib versus sorafenib as second-line treatment for advanced renal cell carcinoma: overall survival analysis and updated results from a randomised phase 3 trial Lancet Oncol 14 2013 552 562
138. K. Mittal, L.S. Wood, and B.I. Rini Axitinib in metastatic renal cell carcinoma Biologics Ther 2 2012 5
139. R. Elisei, M.J. Schlumberger, and S.P. Muller et al. Cabozantinib in progressive medullary thyroid cancer J Clin Oncol 31 2013 3639 3646
140. E. Ghiso, and S. Giordano Targeting MET: why, where and how? Curr Opin Pharmacol 13 2013 511 518
141. E. Van Cutsem, J. Tabernero, and R. Lakomy et al. Intravenous aflibercept versus placebo in combination with irinotecan/5-FU (FOLFIRI) for second-line treatment of metastatic colorectal cancer (MCRC): results of a multinational phase III trial (EFC10262-VELOUR) (ESMO abstract O-0024) Ann Oncol 22 2011
142. B. Rini, C. Szczylik, and N.M. Tannir et al. AMG 386 in combination with sorafenib in patients with metastatic clear cell carcinoma of the kidney: a randomized, double-blind, placebo-controlled, phase 2 study Cancer 118 2012 6152 6161
143. B.J. Monk, A. Proveda, and I. Vergote et al. A phase III, randomized, double-blind trial of weekly paclitaxel plus the angiopoietin 1 and 2 inhibitor, trebananib, or placebo in women with recurrent ovarian cancer:TRINOVA-1 Eur J Cancer 47 2011
144. F.S. Hodi, S.J. O'Day, and D.F. McDermott et al. Improved survival with ipilimumab in patients with metastatic melanoma N Engl J Med 363 2010 711 723
145. S.L. Topalian, F.S. Hodi, and J.R. Brahmer et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
146. B.C. Creelan Update on immune checkpoint inhibitors in lung cancer Cancer Control 21 2014 80 89
147. M.K. Callahan, and J.D. Wolchok At the bedside: CTLA-4- and PD-1-blocking antibodies in cancer immunotherapy J Leukoc Biol 94 2013 41 53
148. O. Hamid, and R.D. Carvajal Anti-programmed death-1 and anti-programmed death-ligand 1 antibodies in cancer therapy Exp Opin Bio Ther 13 2013 847 861
149. O. Casanovas, D.J. Hicklin, G. Bergers, and D. Hanahan Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors Cancer Cell 8 2005 299 309
150. B. Sennino, and D.M. McDonald Controlling escape from angiogenesis inhibitors Nat Rev Cancer 12 2012 699 709
151. H.J. Hammers, H.M. Verheul, and B. Salumbides et al. Reversible epithelial to mesenchymal transition and acquired resistance to sunitinib in patients with renal cell carcinoma: evidence from a xenograft study Mol Cancer Ther 9 2010 1525 1535
152. T.C. Tang, S. Man, and P. Xu et al. Development of a resistance-like phenotype to sorafenib by human hepatocellular carcinoma cells is reversible and can be delayed by metronomic UFT chemotherapy Neoplasia 12 2010 928 940
153. L. Zhang, M. Bhasin, and R. Schor-Bardach et al. Resistance of renal cell carcinoma to sorafenib is mediated by potentially reversible gene expression PloS One 6 2011 e19144
154. E.A. Kuczynski, D.J. Sargent, A. Grothey, and R.S. Kerbel Drug rechallenge and treatment beyond progression - implications for drug resistance Nat Rev Clin Oncol 10 2013 571 587
155. M. Greaves, and C.C. Maley Clonal evolution in cancer Nature 481 2012 306 313
156. J.M. Ebos, C.R. Lee, W. Cruz-Munoz, G.A. Bjarnason, J.G. Christensen, and R.S. Kerbel Accelerated metastasis after short-term treatment with a potent inhibitor of tumor angiogenesis Cancer Cell 15 2009 232 239
157. M. Paez-Ribes, E. Allen, and J. Hudock et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis Cancer Cell 15 2009 220 231
158. F. Shojaei, B.H. Simmons, J.H. Lee, P.B. Lappin, and J.G. Christensen HGF/c-Met pathway is one of the mediators of sunitinib-induced tumor cell type-dependent metastasis Cancer Lett 320 2012 48 55
159. A.S. Chung, M. Kowanetz, and X. Wu et al. Differential drug class-specific metastatic effects following treatment with a panel of angiogenesis inhibitors J Pathol 227 2012 404 416
160. J.C. Welti, T. Powles, and S. Foo et al. Contrasting effects of sunitinib within in vivo models of metastasis Angiogenesis 15 2012 623 641
161. Y. Xu, Q. Li, X.Y. Li, Q.Y. Yang, W.W. Xu, and G.L. Liu Short-term anti-vascular endothelial growth factor treatment elicits vasculogenic mimicry formation of tumors to accelerate metastasis J Exp Clin Cancer Res 31 2012 16
162. T. Takeda, H. Okuyama, Y. Nishizawa, S. Tomita, and M. Inoue Hypoxia inducible factor-1alpha is necessary for invasive phenotype in Vegf-deleted islet cell tumors Sci Rep 2 2012 494
163. R. Grepin, M. Guyot, and M. Jacquin et al. Acceleration of clear cell renal cell carcinoma growth in mice following bevacizumab/Avastin treatment: the role of CXCL cytokines Oncogene 31 2012 1683 1694
164. F. Maione, S. Capano, and D. Regano et al. Semaphorin 3A overcomes cancer hypoxia and metastatic dissemination induced by antiangiogenic treatment in mice J Clin Invest 122 2012 1832 1848
165. A. Casazza, B. Kigel, and F. Maione et al. Tumour growth inhibition and anti-metastatic activity of a mutated furin-resistant Semaphorin 3E isoform EMBO Mol Med 4 2012 234 250
166. W. Zhang, H.C. Sun, and W.Q. Wang et al. Sorafenib down-regulates expression of HTATIP2 to promote invasiveness and metastasis of orthotopic hepatocellular carcinoma tumors in mice Gastroenterology 143 2012 1641 1649
167. E. Hammond, R. Brandt, and K. Dredge PG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma model PloS One 7 2012 e52175
168. S.J. Conley, E. Gheordunescu, and P. Kakarala et al. Antiangiogenic agents increase breast cancer stem cells via the generation of tumor hypoxia Proc Natl Acad Sci U S A 109 2012 2784 2789
169. S. He, G.E. Lamers, and J.W. Beenakker et al. Neutrophil-mediated experimental metastasis is enhanced by VEGFR inhibition in a zebrafish xenograft model J Pathol 227 2012 431 445
170. Q.B. Zhang, H.C. Sun, and K.Z. Zhang et al. Suppression of natural killer cells by sorafenib contributes to prometastatic effects in hepatocellular carcinoma PloS One 8 2013 e55945
171. M. Singh, S.S. Couto, and W.F. Forrest et al. Anti-VEGF antibody therapy does not promote metastasis in genetically engineered mouse tumour models J Pathol 227 2012 417 430
172. D. Miles, N. Harbeck, and B. Escudier et al. Disease course patterns after discontinuation of bevacizumab: pooled analysis of randomized phase III trials J Clin Oncol 29 2011 83 88
173. K.B. Blagoev, J. Wilkerson, W.D. Stein, R.J. Motzer, S.E. Bates, and A.T. Fojo Sunitinib does not accelerate tumor growth in patients with metastatic renal cell carcinoma Cell Rep 3 2013 277 281
174. R.S. Kerbel, E. Guerin, and G. Francia et al. Preclinical recapitulation of antiangiogenic drug clinical efficacies using models of early or late stage breast cancer metastatis Breast 22 Suppl 2 2013 S57 S65
175. B. Escudier, J. Bellmunt, and S. Negrier et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol 28 2010 2144 2150
176. B. Escudier, A. Pluzanska, and P. Koralewski et al. Bevacizumab plus interferon alfa-2a for treatment of metastatic renal cell carcinoma: a randomised, double-blind phase III trial Lancet 370 2007 2103 2111
177. B.I. Rini, S. Halabi, and J.E. Rosenberg et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206 J Clin Oncol 28 2010 2137 2143
178. B.I. Rini, S. Halabi, and J.E. Rosenberg et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 J Clin Oncol 26 2008 5422 5428
179. B.J. Giantonio, P.J. Catalano, and N.J. Meropol et al. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200 J Clin Oncol 25 2007 1539 1544
180. J. Bennouna, J. Sastre, and D. Arnold et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): a randomised phase 3 trial Lancet Oncol 14 2013 29 37
181. A. Sandler, R. Gray, and M.C. Perry et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
182. T.N. Kreisl, L. Kim, and K. Moore et al. Phase II trial of single-agent bevacizumab followed by bevacizumab plus irinotecan at tumor progression in recurrent glioblastoma J Clin Oncol 27 2009 740 745
183. B. Escudier, T. Eisen, and W.M. Stadler et al. Sorafenib for treatment of renal cell carcinoma: Final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trial J Clin Oncol 27 2009 3312 3318
184. M.S. Brose, C. Nutting, and B. Jarzab et al. Sorafenib in locally advanced or metastatic patients with radioactive iodine-refractory differentiated thyroid cancer: The phase III DECISION trial J Clin Oncol 31 suppl 2013 4
185. R.J. Motzer, T.E. Hutson, and P. Tomczak et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 3584 3590
186. R.J. Motzer, T.E. Hutson, and P. Tomczak et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
187. G.D. Demetri, C.R. Garrett, and P. Schoffski et al. Complete longitudinal analyses of the randomized, placebo-controlled, phase III trial of sunitinib in patients with gastrointestinal stromal tumor following imatinib failure Clin Cancer Res 18 2012 3170 3179
188. G.D. Demetri, A.T. van Oosterom, and C.R. Garrett et al. Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial Lancet 368 2006 1329 1338
189. E. Raymond, L. Dahan, and J.L. Raoul et al. Sunitinib malate for the treatment of pancreatic neuroendocrine tumors N Engl J Med 364 2011 501 513
190. C.N. Sternberg, R.E. Hawkins, and J. Wagstaff et al. A randomised, double-blind phase III study of pazopanib in patients with advanced and/or metastatic renal cell carcinoma: final overall survival results and safety update Eur J Cancer 49 2013 1287 1296
191. W.T. van der Graaf, J.Y. Blay, and S.P. Chawla et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial Lancet 379 2012 1879 1886
192. B.I. Rini, B. Escudier, and P. Tomczak et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomised phase 3 trial Lancet 378 2011 1931 1939
193. S.A. Wells Jr, B.G. Robinson, and R.F. Gagel et al. Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial J Clin Oncol 30 2012 134 141
194. A. Grothey, E. Van Cutsem, and A. Sobrero et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 381 2013 303 312
195. G.D. Demetri, P. Reichardt, and Y.K. Kang et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial Lancet 381 2013 295 302
196. E. Van Cutsem, J. Tabernero, and R. Lakomy et al. Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen J Clin Oncol 30 2012 3499 3506